NGNE Neurogene Inc.
Nasdaq · SEC CIK 1404644 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $1.13M 9 sales by 4 insiders
- Filings on record
- 88 since 2021-08-05, latest 2026-07-07 21:08
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Cvijic Christine Mikail | Pres, CFO, Dir | — | $900.0K |
| Cobb Stuart | CSO | — | $141.4K |
| McMinn Rachel | CEO, Dir | — | $74.0K |
| Jordan Julie | Chief Medical Off | — | $18.1K |
Transactions 40
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-07-07 21:08 | 2026-07-06+ | NGNE | Cvijic Christine Mikail | Pres, CFO, Dir | S - Sale | $36.12 | -4,800 | 84.0K | -5% | -$173.4K |
| MT | 2026-07-02 18:42 | 2026-07-01+ | NGNE | Cvijic Christine Mikail | Pres, CFO, Dir | S - Sale | $34.71 | -4,800 | 88.8K | -5% | -$166.6K |
| MT | 2026-05-08 11:51 | 2026-05-06 | NGNE | Cvijic Christine Mikail | Pres, CFO, Dir | S - Sale | $31.25 | -9,600 | 93.6K | -9% | -$300.0K |
| 2026-03-30 | 2026-03-26 | NGNE | Cvijic Christine Mikail | Pres, CFO | S - Sale | $21.62 | -2,558 | 103.2K | -2% | -$55.3K | |
| 2026-03-30 | 2026-03-26 | NGNE | Jordan Julie | Chief Medical Off | S - Sale | $21.89 | -828 | 12.5K | -6% | -$18.1K | |
| 2026-03-30 | 2026-03-26 | NGNE | McMinn Rachel | CEO, Dir | S - Sale | $22.07 | -3,352 | 1.34M | -0.2% | -$74.0K | |
| M | 2026-03-17 | 2026-03-13 | NGNE | Cvijic Christine Mikail | Pres, CFO | S - Sale | $20.81 | -4,045 | 107.5K | -4% | -$84.2K |
| M | 2026-03-17 | 2026-03-13 | NGNE | Cobb Stuart | CSO | S - Sale | $20.81 | -6,797 | 30.5K | -18% | -$141.4K |
| 2026-03-03 | 2026-02-27 | NGNE | Cvijic Christine Mikail | Pres, CFO | S - Sale | $25.11 | -4,800 | 109.8K | -4% | -$120.5K | |
| D | 2026-02-24 | 2026-02-20 | NGNE | McMinn Rachel | CEO, Dir | A - Grant | $0.00 | +25.9K | 1.35M | +2% | $0 |
| D | 2026-02-24 | 2026-02-20 | NGNE | Cvijic Christine Mikail | Pres, CFO | A - Grant | $0.00 | +22.0K | 114.6K | +24% | $0 |
| D | 2026-02-24 | 2026-02-20 | NGNE | Jordan Julie | Chief Medical Off | A - Grant | $0.00 | +4,900 | 13.3K | +58% | $0 |
| 2026-02-24 | 2026-02-20 | NGNE | Cobb Stuart | CSO | A - Grant | $0.00 | +16.5K | 37.3K | +79% | $0 | |
| 2025-05-15 | 2025-05-14 | NGNE | Cobb Stuart | CSO | S - Sale | $15.15 | -6,797 | 20.8K | -25% | -$103.0K | |
| D | 2025-03-28 | 2025-03-26 | NGNE | Cobb Stuart | CSO | A - Grant | $0.00 | +7,200 | 27.6K | +35% | $0 |
| D | 2025-03-28 | 2025-03-26 | NGNE | Cvijic Christine Mikail | Pres, CFO | A - Grant | $0.00 | +20.3K | 92.6K | +28% | $0 |
| D | 2025-03-28 | 2025-03-26 | NGNE | Jordan Julie | Chief Medical Off | A - Grant | $0.00 | +8,400 | 8,400 | New | $0 |
| D | 2025-03-28 | 2025-03-26 | NGNE | McMinn Rachel | CEO, Dir | A - Grant | $0.00 | +23.9K | 1.27M | +2% | $0 |
| 2025-03-17 | 2025-03-13 | NGNE | Cvijic Christine Mikail | Pres, CFO | S - Sale | $16.94 | -4,501 | 72.3K | -6% | -$76.2K | |
| MI | 2024-11-27 | 2024-11-26 | NGNE | AKKARAJU SRINIVAS | 10% | P - Purchase | $25.83 | +48.8K | 1.69M | +3% | +$1.26M |
| 2024-11-25 | 2024-11-22 | NGNE | McMinn Rachel | CEO, Dir | P - Purchase | $20.40 | +47.5K | 1.30M | +4% | +$969.0K | |
| 2024-11-25 | 2024-11-22 | NGNE | Cvijic Christine Mikail | Pres, CFO | P - Purchase | $20.48 | +24.0K | 76.8K | +45% | +$491.5K | |
| D | 2024-03-14 | 2024-03-13 | NGNE | Cvijic Christine Mikail | Pres, CFO | A - Grant | $0.00 | +31.9K | 52.8K | +152% | $0 |
| D | 2024-03-14 | 2024-03-13 | NGNE | Cobb Stuart | CSO | A - Grant | $0.00 | +20.4K | 20.4K | New | $0 |
| DMI | 2023-10-10 | 2023-10-05 | NGNE | Baker Bros. Advisors (GP) LLC | Dir, 10% | X - OptEx | — | +592.6K | 155.9K | New | — |
| MI | 2023-08-17 | 2023-08-15+ | NGNE | Baker Brothers Life Sciences LP | Dir, 10% | P - Purchase | $0.6395 | +2.29M | 481.4K | New | +$1.46M |
| D | 2023-08-14 | 2023-08-11 | NGNE | Smith Sean Michael | Interim CFO, Prin Acct Off | S - Sale+OE | $0.62 | -1,323 | 21.6K | -6% | -$820.26 |
| D | 2023-08-14 | 2023-08-10 | NGNE | Smith Sean Michael | Interim CFO, Prin Acct Off | M - OptEx | $0.00 | +5,000 | 23.0K | +28% | $0 |
| D | 2023-04-04 | 2023-04-03 | NGNE | Patel Priti | Former Chief Medical Off | S - Sale+OE | $0.69 | -3,769 | 37.3K | -9% | -$2,601 |
| D | 2023-04-04 | 2023-03-31 | NGNE | Patel Priti | Former Chief Medical Off | M - OptEx | $0.00 | +10.0K | 41.1K | +32% | $0 |
| D | 2023-02-03 | 2023-02-01 | NGNE | Smith Sean Michael | Principal Accounting Off | M - OptEx | $0.00 | +12.5K | 19.3K | +184% | $0 |
| D | 2023-02-03 | 2023-02-02 | NGNE | Smith Sean Michael | Principal Accounting Off | S - Sale+OE | $0.6 | -3,316 | 16.0K | -17% | -$1,990 |
| D | 2023-02-03 | 2023-02-02 | NGNE | Patel Priti | Chief Medical Off | S - Sale+OE | $0.6 | -14.4K | 31.1K | -32% | -$8,628 |
| D | 2023-02-03 | 2023-02-01 | NGNE | Patel Priti | Chief Medical Off | M - OptEx | $0.00 | +35.0K | 45.5K | +335% | $0 |
| D | 2022-08-12 | 2022-08-10 | NGNE | Smith Sean Michael | Principal Accounting Off | S - Sale+OE | $0.99 | -1,655 | 6,776 | -20% | -$1,638 |
| D | 2022-08-12 | 2022-08-10 | NGNE | Smith Sean Michael | Principal Accounting Off | M - OptEx | $0.00 | +5,000 | 8,431 | +146% | $0 |
| D | 2022-05-03 | 2022-04-30 | NGNE | Patel Priti | Chief Medical Off | M - OptEx | $0.00 | +10.0K | 12.0K | +500% | $0 |
| D | 2022-05-03 | 2022-05-02 | NGNE | Patel Priti | Chief Medical Off | S - Sale+OE | $1.22 | -5,538 | 6,462 | -46% | -$6,756 |
| MI | 2021-08-26 | 2021-08-25 | NGNE | DRACHMAN JONATHAN G | Pres, CEO, Dir | P - Purchase | $6.45 | +50.0K | 25.0K | New | +$322.5K |
| 2021-08-26 | 2021-08-24 | NGNE | DRACHMAN JONATHAN G | Pres, CEO, Dir | P - Purchase | $6.11 | +100.0K | 2.35M | +4% | +$611.0K |
Purchase Sale Sale after option exercise All abbreviations